参考文献/References:
[1]Zeng GG,Tang SS,Jiang WL,et al. Apelin-13:a protective role in vascular diseases[J]. Curr Probl Cardiol,2024,49(1 Pt B):102088.
[2]Sun X,Zhang Y,Qi X,et al. Impact of apelin-13 on the development of coronary artery ectasia[J]. Acta Cardiol Sin,2020,36(3):216-222.
[3]中国心血管健康与疾病报告编写组,胡盛寿,王增武. 《中国心血管健康与疾病报告2022》概要[J]. 中国介入心脏病学杂志,2023,31(7):485-508.
[4]马萍,韩笑,王广勇,等. 老年CHD合并糖尿病患者血清Apelin-13水平及与Gensini评分的关系[J]. 中国老年学杂志,2022,42(3):516-519.
[5]Wen R,Huang R,Xu K,et al. Beneficial effects of Apelin-13 on metabolic diseases and exercise[J]. Front Endocrinol (Lausanne),2023,14:1285788.
[6]孙旭森,张宇凡,李沅洋,等.Apelin-13在冠状动脉粥样硬化病变临床诊断中的应用价值[J].天津医科大学学报,2019,25(06):572-576.
[7]王英慧,陈天伦,沈青青. Lp(a)、ApoB及Apelin-13与老年CHD患者颈动脉粥样硬化斑块的相关性[J]. 保健医学研究与实践,2023,20(11):41-45,51.
[8]Cai X,Liu L,Xia F,et al. Apelin-13 reverses bupivacaine-induced cardiotoxicity:an experimental study[J]. Braz J Anesthesiol,2024,74(3):844501.
[9]张彦宏,张波,李显东. Apelin-13对急性心肌梗死家兔的治疗作用[J].中国实用医药,2020,15(7):194-196.
[10]Ilaghi M,Soltanizadeh A,Amiri S,et al. The apelin/APJ signaling system and cytoprotection:Role of its cross-talk with kappa opioid receptor[J]. Eur J Pharmacol,2022,936:175353.
[11]Popov SV,Maslov LN,Mukhomedzyanov AV,et al. Apelin is a prototype of novel drugs for the treatment of acute myocardial infarction and adverse myocardial remodeling[J]. Pharmaceutics,2023,15(3):1029.
[12]陈君,马娜,顾明,等. 老年急性心肌梗死患者PCI前血清miR-503、Apelin-13水平与术后左心室重构的关系[J]. 山东医药,2022,62(34):11-15.
[13]Bu LL,Yuan HH,Xie LL,et al. New dawn for atherosclerosis:Vascular endothelial cell senescence and death[J]. Int J Mol Sci,2023,24(20):15160.
[14]Song J,Tang J,Zhang Z,et al. Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension[J]. Chin Med J (Engl),2022,135(09):1019-1026.
[15]Yang R,Fang W,Liang J,et al. Apelin/APJ axis improves angiotensin II-induced endothelial cell senescence through AMPK/SIRT1 signaling pathway[J]. Arch Med Sci,2018,14(4):725-734.
[16] Kadoglou NP,Lampropoulos S,Kapelouzou A ,et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY[J]. Transl Res,2010 ,155(5):238-246.
[17]Wyderka R,Diakowska D,?oboz-Rudnicka M,et al. Influence of the apelinergic system on conduction disorders in patients after myocardial infarction[J]. J Clin Med,2023,12(24):7603.
[18]Gergics M,Pham-Dobor G,Kurdi C,et al. Apelin-13 as a potential biomarker in critical illness [J]. J Clin Med,2023,12(14):4801.
[19]孙喜军,刘伟,王欣,等. 急性心肌梗死患者血清S100A4、Apelin-13表达改变与心肌损伤的相关性研究[J]. 中国急救复苏与灾害医学杂志,2024,19(1):1-3,19.
[20]Zhou Y,Wang Y,Qiao S. Apelin a potential marker of coronary artery stenosis and atherosclerotic plaque stability in acs patients[J]. Int Heart J,2014,55(3):204-212.
[21]王罗卿,孙黎明,王怡练,等. 血清Apelin-13预测功能性心肌缺血的价值[J]. 中国心血管病研究,2016,14(8):717-719,765.
[22]刘丹,刘增长. 外源性apelin-13对大鼠动脉粥样硬化形成的影响[J]. 第三军医大学学报,2014,36(17):1822-1827.
[23]Fraga‐Silva RA,Seeman H,Montecucco F,et al. Apelin‐13 treatment enhances the stability of atherosclerotic plaques[J]. Eur J Clin Invest,2018,48(3):e12891.
[24]Zhong S,Guo H,Wang H,et al. Apelin-13 alleviated cardiac fibrosis via inhibiting the PI3K/Akt pathway to attenuate oxidative stress in rats with myocardial infarction-induced heart failure[J]. Biosci Rep,2020,40(4):BSR20200040.
[25]Respekta N,Pich K,Dawid M,et al. The apelinergic system:apelin,ELABELA,and APJ action on cell apoptosis:anti-apoptotic or pro-apoptotic effect?[J]. Cells,2022,12(1):150.
[26]张波,张彦宏,陈立涛. Apelin-13对急性心肌梗死家兔心肌重构的影响[J]. 中国急救医学,2019,39(6):587-590.
[27]Azizi Y,Faghihi M,Imani A,et al. Post-infarct treatment with [Pyr1]apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats[J]. Eur J Pharmacol,2015,761:101-108.
[28]Li L,Zeng H,Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction[J]. Am J Physiol Heart Circ Physiol,2012,303(5):H605-H618. [29]Rossin D,Vanni R,Lo Iacono M,et al. APJ as Promising therapeutic target of peptide analogues in myocardial infarction-and hypertension-induced heart failure[J]. Pharmaceutics,2023,15(5):1408.
[30]Liu W,Yan J,Pan W,et al. Apelin/Elabela-APJ:a novel therapeutic target in the cardiovascular system[J]. Ann Transl Med,2020,8(5):243.
[31]Gao S,Chen H. Therapeutic potential of apelin and Elabela in cardiovascular disease[J]. Biomed Pharmacother,2023,166:115268.
[32]Azizi Y,Imani A,Fanaei H,et al. Post-infarct treatment with [Pyr 1] apelin-13 exerts anti-remodelling and anti-apoptotic effects in rats’ hearts[J]. Kardiol Pol,2017,75(6):605-613.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(11):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(11):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(11):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(11):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(11):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]